Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 20, 2023.

Details of the event are as follows:
Panel: “Off-the-Shelf CART – Current Snapshot”
Date: Thursday, April 20, 2023
Time: 11:00 a.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005139/en/

Adicet Bio., Inc.
Investor and Media Contacts

Anne Bowdidge
[email protected]

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Source: Adicet Bio, Inc.

You May Also Be Interested In

• 9-Time GRAMMY® Winner Sheryl Crow and Sens. John Cornyn and Amy Klobuchar to Be Honored at the GRAMMYs on the Hill® Awards
• Intero’s David Guardanapo Inducted to NAR’s 30 Under 30 Class of 2024
• OFL urges Mayor Andrea Horwath to oppose the privatization of Hamilton LRT